A day in the life of an oncology registrar
It’s Monday morning and I arrive at the oncology outpatients department to do a clinic with my consultant. It’s overbooked — yet again. The reminder alarm on my smartphone starts beeping. The alert flashes that I have to submit my oncology advanced training paperwork today and try to get hold of my supervisor to sign it off, and that I’m doing a journal club presentation tomorrow.
So, things are already sounding busy for the next 24 hours at least. I take a deep breath and get ready to start my clinic.
The outpatients’ waiting room is already full and the reception staff seem to be panicking already. I pick up the case notes of a 29-year-old man who is attending the clinic to be told the results of his restaging scan for melanoma and to discuss treatment options. I start thinking that there have been a lot of developments recently in the field of melanoma.
Meanwhile, my consultant, who knows this patient very well, walks into the clinic central meeting room. He asks me, “Dr Burnt, what do you know about the mechanism of action and efficacy of targeted therapy and immunotherapy (with ipilimumab) in advanced melanoma?” I say I have heard they are good, but to what extent, I don’t know exactly. Obviously, had I read the pile of recent issues of the New England Journal of Medicine lying on my shelf still covered in the plastic wrapping, I might have been able to answer his question.
My consultant tells me that I need to stay up to date with the latest developments in the field of oncology and to read the literature regularly.
He then asks me to compare the latest scans for this patient with previous scans for any disease progression. After about 5 minutes, I still have not located the retroperitoneal nodes and external iliac nodes mentioned in the report in either scan, let alone compare them for progression.
I am further told to build up my radiology skills to be able to accurately compare the scans and also for reporting on clinical trials.
My consultant then shows me a few slides of ipilimumab Phase III trial results in advanced melanoma, commenting that the response rate seems to be low (10%–15%) and, looking at the graphs, that there is no difference in progression-free survival — however, there is a survival benefit. His next questions are: “What is the significance of the delayed separation of Kaplan–Meier survival curves in this trial? And what about the prognostic markers on multivariate analyses?” My replies, as before, are not convincing.
I am told to work on my statistics, as this skill is needed to better make sense of the data.
Finally, after a quick 5-minute advanced melanoma-treatment update session from my consultant, I go and see the patient.
The patient is accompanied by his wife and mother. I tell him: “Unfortunately, you have widespread metastatic disease and we have identified a brain metastasis as well.” This spreads a huge wave of disappointment and grief throughout the room. Both wife and mother start crying.
Patient: I have heard on television about good results with a magic tablet (targeted therapy) in advanced melanoma.
Dr Burnt: You do not have a specific mutation, so that treatment will not work for you.
Patient: What about a clinical trial option?
Dr Burnt: Unfortunately, because brain metastasis is present, this would exclude you from any current trial.
Mother: Will chemotherapy work?
Dr Burnt: I’m sorry, but this is unlikely, given poor response rates to this treatment.
There is a long, silent, unhappy pause in the room …
Wife: How long does my husband have? Will he be there at the birth of our second child in 5 months’ time?
Dr Burnt (in shock, unaware that the couple were expecting a second child): It’s very difficult to say, but probably less than 6 months and it may even be less than that.
Patient: Is there anything, doctor, that you can do for me? What about the immune-stimulating drug I read about on the internet? I don’t want to die! I have a 14-month-old son and we’re expecting our second child … I’m only 29, I have many years yet to live … what you are saying can’t be true … who will look after my family and young kids … I have to keep working to pay my mortgage.
Dr Burnt: Unfortunately, we can’t access this drug in Australia as it’s very expensive. What I have told you about your prognosis is also, unfortunately, true.
I move on to the next patient. After seeing 10 patients, I realise it is now 3 pm. As usual, I’ve not had my lunch break yet. But at the back of my mind, I can still feel the sorrow and pain of the young couple that I saw earlier today. There was nothing very promising that I could offer them.
I felt sad and depressed. I kept thinking about the consultation for the rest of that day. I also felt the need and pressure to enhance my professional skills.
This is just one example of the many unfortunate scenarios that most of my colleagues, junior and senior, looking after patients with cancer, frequently have to face. Difficult consultations like the one above, administrative pressures, social dilemmas, working long hours and the constant demand to perform at high efficiency are a recipe for what many call “burnout”. This is especially relevant within the oncology subspecialty, where we are frequently dealing with terminally ill patients and their families.
a syndrome … present in many individuals under constant pressure. Physicians in particular are overloaded with the demands of caring for sick patients … The symptoms and signs of burnout include emotional exhaustion, cynicism, and perceived clinical ineffectiveness, and a sense of depersonalization in relationships with co-workers, patients, or both.1
These feelings can manifest as irritability, increased anger and detachment from the social environment, very much in contrast to the individual’s normal behaviour.1 However, it is usually not the case that individuals can self-diagnose the early signs of burnout.
Burnout in oncologists has been reported in the literature. A nationwide survey of 740 (56%) members of the Clinical Oncology Society of Australia was conducted to determine the prevalence and predictors of burnout in the Australian oncology workforce.2 High levels of emotional exhaustion were present in 33% of participants. In the United States, a survey of 598 members of the American Society of Clinical Oncology found that 56% reported burnout, with feelings of sense of failure (56%), depression (34%), disinterest in practice (20%) and boredom (18%).3
Burnout has also been linked to low patient satisfaction, errors in decision making, unprofessional behaviour and deterioration of clinical skills. It may also affect the personal life of physicians in the form of substance abuse, depression and divorce.
I believe there is an urgent need to recognise and formulate interventions for at-risk medical staff in chronic stress and relational trauma settings. Early recognition and rectification of burnout in oncologists is needed to ensure the wellbeing, not only of doctors but also of our patients, who deserve optimal medical and psychological support provided by caring and competent medical practitioners.